Amgen's Neulasta Succeeds in Phase 3 Cancer Trial

Biotech giant Amgen (NASDAQ: AMGN  ) announced in a press release Saturday that its PAVES phase 3 trial to evaluate colorectal cancer patients taking the white blood cell-boosting drug Neulasta met its primary endpoint.

In the trial, Neulasta significantly reduced the incidence of febrile neutropenia, which is low white blood cell count combined with fever. The drug more than halved the percent of chemotherapy patients contracting grade 3 or 4 febrile neutropenia as compared to a placebo group, the company said, cutting the incidence from 5.7% to 2.4%.

Amgen Executive Vice President of Research and Development Dr. Sean E. Harper was quoted in the press release as saying, "In addition to providing new data on Neulasta, we believe PAVES will provide valuable information to the oncology community on commonly used chemotherapy regimens."

The company will provide further details on other trial endpoints, such as overall survival and response rate, later. Neulasta was first approved by the FDA back in 2002, with Amgen continuing to provide more data on its blockbuster drug through follow-up trials. Neulasta sold more than $4 billion around the world for the full year 2012, with sales growing 4%.

link


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2218607, ~/Articles/ArticleHandler.aspx, 10/21/2014 7:52:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement